Cargando…
Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition
The angiogenesis inhibitor sunitinib is a tyrosine kinase inhibitor that acts mainly on the VEGF and PDGF pathways. We have previously shown that sunitinib is sequestered in the lysosomes of exposed tumor and endothelial cells. This phenomenon is part of the drug-induced resistance observed in the c...
Autores principales: | Nowak-Sliwinska, P, Weiss, A, van Beijnum, J R, Wong, T J, Kilarski, W W, Szewczyk, G, Verheul, H M W, Sarna, T, van den Bergh, H, Griffioen, A W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669819/ https://www.ncbi.nlm.nih.gov/pubmed/25675301 http://dx.doi.org/10.1038/cddis.2015.4 |
Ejemplares similares
-
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2012) -
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization
por: Weiss, Andrea, et al.
Publicado: (2014) -
A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7)
por: van Beijnum, Judy R., et al.
Publicado: (2017) -
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
por: Weiss, Andrea, et al.
Publicado: (2015) -
Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2018)